Swiss drugmaker Siegfried Holding reported record 2025 profit margins but tempered its 2026 growth forecast due to limited visibility on a key unconfirmed contract in its drug substances business, signaling cautious investor sentiment.

Chief Executive Marcel Imwinkelried explicitly stated the company adopted a deliberately cautious stance, warning that the pending customer confirmation for a large contract could negatively impact sales growth in Drug Substances during 2026. This caution led Siegfried to guide for low-single-digit growth in Drug Products and Drug Substances, excluding the impact of a recent US and Australian capacity acquisition.

While Siegfried's core EBITDA margin expanded to a record 23.5% in 2025, driven by a 9.3% increase in core EBITDA to CHF 312.3 million, the company's forward guidance remains constrained. The Drug Substances cluster, contributing CHF 916.3 million, saw local currency growth of 4.3%, but the uncertainty surrounding the large contract overshadowed the overall positive performance. Siegfried's net debt ratio stood at 1.5 times core EBITDA, and free cash flow improved to negative CHF 3.1 million from CHF 11.6 million in 2024.